FDA Flags GLP‑1 Blindness Risk

The U.S. Food and Drug Administration has ordered warning labels on all GLP‑1 drugs after finding a potential increased risk of nonarteritic anterior ischemic optic neuropathy (NAION), a rare condition that can cause sudden, permanent vision loss. The decision draws on a 2024 JAMA Ophthalmology signal, adverse‑event reports, and analyses across clinical trials, even though no clear biological mechanism has been identified. — This regulatory step reframes GLP‑1s from a fast‑moving lifestyle and diabetes therapy story into a public‑health safety and prescribing policy issue with implications for patients, clinicians, insurers and drugmakers.